Lilly's SURPASS-1 results published in The Lancet show tirzepatide's superior A1C and body weight reductions versus placebo in adults with type 2 diabetes

- A1C change: -1.87% (5 mg), -1.89% (10 mg), -2.07% (15 mg), +0.04% (placebo)
- Weight reduction: -7.0 kg (-7.9%, 5 mg), -7.8 kg (-9.3%, 10 mg), -9.5 kg (-11.0%, 15 mg), -0.7 kg (-0.9%, placebo)
- Percent of participants achieving A1C <7%: 87% (5 mg), 92% (10 mg), 88% (15 mg), 20% (placebo)
- Percent of participants achieving A1C <5.7%: 34% (5 mg), 31% (10 mg), 52% (15 mg), 1% (placebo)
- Change in FSG: -43.6 mg/dL (5 mg), -45.9 mg/dL (10 mg), -49.3 mg/dL (15 mg), +12.9 mg/dL (placebo)
- A1C reduction: -1.75% (5 mg), -1.71% (10 mg), -1.69% (15 mg), -0.09% (placebo)
- Weight reduction: -6.3 kg (5 mg), -7.0 kg (10 mg), -7.8 kg (15 mg), -1.0 kg (placebo)
- Percent of participants achieving A1C <7%: 82% (5 mg), 85% (10 mg), 78% (15 mg), 23% (placebo)
- Percent of participants achieving A1C <5.7%: 31% (5 mg), 27% (10 mg), 38% (15 mg), 1% (placebo)
- Change in FSG: -39.6 mg/dL (5 mg), -39.8 mg/dL (10 mg), -38.6 mg/dL (15 mg), +3.7 mg/dL (placebo)